Izrael - angličtina - Ministry of Health

teva israel ltd - gabapentin - capsules - gabapentin 300 mg - gabapentin - gabapentin - epilepsy :- gabapentin is indicated as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in adults and adolescents ( age 12 and up ) with epilepsy.- treatment of neuropathic pain- gabapentin is indicated for the treatment of neuropathic pain in diabetic neuropathy or postherpetic neuropathy(neuralgia) in adults.

Izrael - angličtina - Ministry of Health

teva pharmaceutical industries ltd, israel - gabapentin - capsules - gabapentin 300 mg - gabapentin - gabapentin - epilepsy :- gabapentin is indicated as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in adults and adolescents ( age 12 and up ) with epilepsy.- treatment of neuropathic pain- gabapentin is indicated for the treatment of neuropathic pain in diabetic neuropathy or postherpetic neuropathy(neuralgia) in adults.

Izrael - angličtina - Ministry of Health

teva israel ltd - gabapentin - capsules - gabapentin 400 mg - gabapentin - gabapentin - epilepsy :- gabapentin is indicated as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in adults and adolescents ( age 12 and up ) with epilepsy.- treatment of neuropathic pain- gabapentin is indicated for the treatment of neuropathic pain in diabetic neuropathy or postherpetic neuropathy(neuralgia) in adults.

Izrael - angličtina - Ministry of Health

teva pharmaceutical industries ltd, israel - gabapentin - capsules - gabapentin 400 mg - gabapentin - gabapentin - epilepsy :- gabapentin is indicated as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in adults and adolescents ( age 12 and up ) with epilepsy.- treatment of neuropathic pain- gabapentin is indicated for the treatment of neuropathic pain in diabetic neuropathy or postherpetic neuropathy(neuralgia) in adults.

Izrael - angličtina - Ministry of Health

teva pharmaceutical industries ltd, israel - gabapentin - tablets - gabapentin 600 mg - gabapentin - gabapentin - epilepsy :- gabapentin is indicated as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in adults and adolescents ( age 12 and up ) with epilepsy.- treatment of neuropathic pain- gabapentin is indicated for the treatment of neuropathic pain in diabetic neuropathy or postherpetic neuropathy(neuralgia) in adults.

Izrael - angličtina - Ministry of Health

teva pharmaceutical industries ltd, israel - gabapentin - tablets - gabapentin 800 mg - gabapentin - gabapentin - epilepsy :- gabapentin is indicated as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in adults and adolescents ( age 12 and up ) with epilepsy.- treatment of neuropathic pain- gabapentin is indicated for the treatment of neuropathic pain in diabetic neuropathy or postherpetic neuropathy(neuralgia) in adults.

Izrael - angličtina - Ministry of Health

teva israel ltd - calcium folinate - tablets - calcium folinate 16.2 mg - detoxifying agents for antineoplastic treatment - counteracts the action of folic acid antagonists. improves blood picture in megaloblastic anemias due to folate deficiency.

Izrael - angličtina - Ministry of Health

teva israel ltd - pravastatin sodium - tablets - pravastatin sodium 40 mg - hmg coa reductase inhibitors - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate. *primary prevention of coronary events: in hypercholesterolemic patients whthout clinically evident coronary heart disease pravastatin is indicated to: - reduce the risk of myocardial infarcton. - reduce the risk for revascularization. - reduce the risk of deaths due to cardiovascular causes with no increase in deaths from non-cardiovascular causes. *secondary prevention of cardiovascular events: atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: - slow the progression of coronary atherosclerosis. - reduce the risk of acute coronary events. myocardial infarction: in patients with previous myocardial infarction and normal cholesterol levels pravastatin is indicated to: - reduce the risk of recurrent myocardial infarction. - reduce the risk of undergoing myocardial revascularization procedures. - reduce the risk of stroke and transient ischemic attack (tia). *hypercholesterolemia and mixed dyslipidemia: pravastatin is indicated as an adjunct to diet to reduce elevated total-c ldl-c and tg levels in patients with primary hypercholesterolemia and mixed dyslipidemia (fredrickson type iia and iib).

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

teva b.v. - pregabalin - capsules hard - 225 milligram - antiepileptics - antiepileptics, other antiepileptics - it a is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation and for the treatment of generalised anxiety disorder (gad) in adults

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

teva b.v. - rasagiline - tablet - 1 milligram(s) - monoamine oxidase b inhibitors; rasagiline - anti-parkinson-drugs, monoamine oxidase -b inhibitors - rasagiline teva is indicated for the treatment of idiopathic parkinson’s disease (pd) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.